Skip to main content

Advertisement

Fig. 1 | Journal of Translational Medicine

Fig. 1

From: High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions

Fig. 1

Differences in the expression of ETS2 in AML. a AML-BM cases (n = 30) compared with NBM samples (n = 17), b AML-BM cases (n = 62) compared with NBM samples (n = 42), c relative expression of ETS2 in the different NCCN-risk subgroup (good, intermediate and poor) of AML cases, d associations between ETS2 expression and other classic prognostic biomarkers in AML cases (FLT3-ITD and the mutation of NPM1 and CEBPA)

Back to article page